GlassScriptPhysician profile
Linda Le
NPI 1205644143
$1,568.56
in general payments reported to CMS, 2019-2025
25 companies · $1,569 in 2025
The $1,569 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,448.57 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $186.39 | 2025 | Nucala, Trelegy Ellipta |
| Incyte Corporation | $183.48 | 2025 | Opzelura, Opzelura, Jakafi |
| Astrazeneca Pharmaceuticals LP | $163.95 | 2025 | Tezspire, Fasenra, Lynparza |
| Csl Behring | $146.86 | 2025 | Andembry, Haegarda |
| Novartis Pharmaceuticals Corporation | $137.75 | 2025 | |
| Gilead Sciences, INC. | $131.56 | 2025 | |
| Astellas Pharma US INC | $99.99 | 2025 | |
| Aveo Pharmaceuticals, INC. | $52.27 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.16 | 2025 | |
| Exelixis INC. | $38.91 | 2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $38.39 | 2025 | Dupixent |
| Biocryst US Sales Co., LLC | $36.97 | 2025 | Orladeyo |
| Merck Sharp & Dohme LLC | $30.55 | 2025 | Keytruda |
| Ars Pharmaceuticals Operations, INC. | $28.45 | 2025 | Neffy |
| Eisai INC. | $28.15 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28.14 | 2025 | Jaypirca, Verzenio |
| Tersera Therapeutics LLC | $27.88 | 2025 | Xermelo |
| Rigel Pharmaceuticals, INC. | $26.10 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Abbvie INC. | $25.68 | 2025 | |
| Karyopharm Therapeutics INC. | $24.18 | 2025 | Xpovio |
| Amgen INC. | $19.32 | 2025 | Tezspire |
| Pharmacosmos Therapeutics INC. | $17.24 | 2025 | Monoferric |
| Servier Pharmaceuticals LLC | $16.97 | 2025 | |
| Azurity Pharmaceuticals, INC. | $15.42 | 2025 | Danziten |
| Recordati_rare_diseases_inc. | $13.80 | 2025 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.